- Long-lasting antibody persistence was comparable in older (65+) and younger adults
- Long-term antibody persistence is a key competitive advantage for a vaccine targeting unpredictable outbreak diseases like chikungunya
Saint-Herblain (France), September 30, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported positive antibody persistence data four years after vaccination with a single dose of its chikungunya vaccine IXCHIQ®. The results are in line with Valneva’s expectations for this vaccine, confirming a strong and long-lasting antibody persistence across all age groups investigated. The four-year persistence data are in line with previous persistence data [1],[2],[3], further highlighting a key advantage of the vaccine.
To access the full release, please click on the PDF below.